GH Research reports its Q1 2022 results. Net loss of $5.8 million. Cash position of $270.8 million as of March 31, 2022.
Seelos Therapeutics Receives a Notice of Allowance in the U.S. for an Additional Patent for SLS-007
Seelos Therapeutics announces receiving its Notice of Allowance from the USPTO for SLS-007 as a method of treatment.
Awakn Life Sciences Completes World's First Ketamine Treatment Study for a Range of Behavioral Addictions
Awakn Life Sciences announce promising results from the first study of ketamine-assisted therapy for behavioral addictions, and will be initiating a larger follow-up study.
Mydecine Announces Size of Previously Announced Overnight Marketed Public Offering of Units
Mydecine Innovations Group announces the issuance of 3,478,260 units at a unit price of CAD$1.15, for gross proceeds of up to CAD$4 million.
Novamind Launches Group Psychedelic Treatment for Frontline Workers
Novamind announces the full-scale launch of Frontline KAP, group-based ketamine-assisted therapy for frontline healthcare workers suffering from burnout/stress/trauma, at select clinic locations.
U.K. Member of Parliament Crispin Blunt To Inaugurate Psilocybin Cultivation Facility At Optimi Health Grand Opening
Optimi Health announces that UK MP, Cristin Blunt will be appearing as a guest speaker at the grand opening ceremony for its Princeton, B.C. cultivation facility.
MindMed Reports Topline Data From Phase 1 Trial of MM-110 in Development for the Treatment of Opioid Withdrawal
MindMed announces positive safety and tolerability results from its Phase 1 clinical trial of MM-110 (18-MC) as a treatment for opioid withdrawal.
Albert Labs Granted Health Canada Licence
Albert Labs announces the receipt of its Dealer's License from Health Canada, allowing possession/sale/delivery of psilocybin and other controlled substances.
Awakn Life Sciences Appoints UK Leader in Addictions Psychiatry, Dr. Arun Dhandayudham, as Chief Medical Officer
Awakn Life Sciences announces the appointment of noted expert in addictions psychiatry, Dr. Arun Dhandayudham as its new CMO.
Optimi Health Acquires Extensive Catalog of Psychedelic and Functional Mushroom Genetics
Optimi Health announces the acquisition of a diverse catalogue of psilocybin and functional mushroom strains intended for cultivation.
MindMed Announces At-The-Market Offering
MindMed announces an at-the-market financing with a prospectus authorizing share sales of up to $100,000,000. Not open to Canadian investors.
Cybin to Participate in NYSE Trading Bell Ceremony on May 18, 2022
Cybin Inc announces that it will take part in the NYSE's "morning bell" ceremony for the May 18th trading session.
